NFKB1 and asthma: Intravenous administration of NF-κB subunit p65 ASO, either prophylactically or therapeutically, was able to inhibit all the asthmatic symptoms, including BAL fluid eosinophilia, elevation of Th2 cytokines, serum lgE level, and AHR in a mouse asthma model [57].